Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Clarient Partner on CLL Test

NEW YORK (GenomeWeb News) – CombiMatrix announced this morning that it will collaborate with Clarient in marketing and selling CombiMatrix’s HemeScan, a prognostic and diagnostic monitoring tool, for chronic lymphocytic leukemia.
 
The test was developed by CombiMatrix in collaboration with researchers at the MD Anderson Cancer Center in Houston, the University of Texas Health Sciences Center in San Antonio, and the Netherlands Cancer Institute in Amsterdam.
 
Cancer diagnostics services lab Clarient will market the tests to pathologists, oncologists, and patients, under the agreement.
 
According to CombiMatrx, the test provides prognostic marker precision with simultaneous diagnostic monitoring of the entire genome in CLL. The firm said that the test also has been validated for acute lymphoblastic leukemia and myelodysplastic syndrome, and it is currently being tested for multiple myeloma.
 
CombiMatrix said there are more than 10,000 new cases of CLL annually in the US and over 150,000 patients living with the disease.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.